Crystalcryoglobulinemia-induced kidney disease

Leflot, Sophie; Vekemans, Marie-Christiane; Lambert, Catherine; Demoulin, Nathalie; Aydın, Selda; Leroy, P; Morelle, Johann

doi:10.1016/j.clml.2019.09.535

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemodialysis and plasma exchange were initiated and treatment commenced with bortezomib, cyclophosphamide and dexamethasone. Skin lesions improved but the patient remained hemodialysis dependent [75]. Leung et al report a case of bilateral renal artery thrombosis associated with cryo-crystaloglobulinemia in a patient with MGUS [71].…”

Section: Cryofibrinogenemiamentioning

confidence: 99%

Monoclonal Gammopathy of Thrombotic Significance

Gkalea

Fotiou

Dimopoulos

et al. 2023

Cancers

View full text Add to dashboard Cite

The current review provides an overview of the thrombotic risk observed in patients with MG who do not otherwise require treatment. We discuss clinical and biomarker studies that highlight the heterogenous hemostatic profile observed in these patients and how knowledge has evolved over the past 20 years. Biomarker studies suggest shared biologic features between multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), which involves both hypercoagulability and platelet activation. Hemostatic abnormalities identified in MGUS patients cannot be translated into clinical practice as they lack correlation to clinical events. The prothrombotic phenotype of MGUS patients has not been ascertained yet, but novel data on coagulation markers are promising. We also review rare conditions associated with the thrombogenic properties of the monoclonal protein that predispose to arterial, venous or microthrombotic events and demonstrate that the M-protein can be linked to clinically significant thrombotic events. Cryoglobulinemia, cryofibrinogenemia, cryo-crystaloglobulinemia and MG-related antiphospholipid syndrome are reviewed. We propose the new umbrella term “monoclonal gammopathy of thrombotic significance” (MGTS) to refer to significant, recurrent thrombotic events in patients with MGUS that provide a rationale for targeting the underlying plasma cell clone. Identifying MGUS patients at high risk for thrombotic events is currently a challenge.

show abstract

Section: Cryofibrinogenemiamentioning

confidence: 99%